Abstract
Recent evidence suggests the existence of a diversity of neuronal nicotinic acetylcholine receptor (nAChRs) subtypes with a wide distribution in brain, that each subtype may be involved in mediating specific functions/behaviors, and that these subtypes have a defined pharmacology that may be selectively targeted (Arneric et al., 1995a). The pharmacologic diversity of neuronal nAChR subtypes suggests the possibility of developing selective compounds which would have more favorable side-effect profiles than existing agents which generally exhibit low selectivity. This broader class of agents, collectively called cholinergic channel modulators (ChCMs) selectively activate some subtypes of nAChRs (i.e. Cholinergic Channel Activators, ChCAs) or inhibit the function of other subtypes (Cholinergic Channel Inhibitors, ChCIs).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
